1. Continuous therapy in HHV-8 negative Multicentric Castleman Disease and prolonged progression-free survival
- Author
-
Yi Liu, Xuejiao Yin, Shengnan Ding, Jiaying Ge, Liya Ma, Min Yang, Xuxia Luo, Chengli Zhong, Sishi Fang, Qiumei Yao, Li Zhu, Wenjuan Yu, Liping Mao, Juying Wei, Xingnong Ye, De Zhou, Hongyan Tong, Haitao Meng, Jie Jin, and Liangshun You
- Subjects
Castleman Disease ,HHV-8 negative Multicentric Castleman Disease ,Continuous therapy ,Diseases of the blood and blood-forming organs ,RC633-647.5 ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
Abstract The optimal treatment endpoints and duration of continuous therapy for multicentric Castleman disease (MCD) remain controversial. We retrospectively analyzed data from 123 patients with Human Herpesvirus (HHV)-8 negative MCD. We demonstrated that continuous therapy significantly enhanced progression-free survival (PFS) in patients who achieved an optimal response after initial treatment. These findings underscore the critical role of continuous therapy in HHV-8 negative MCD. Further studies with larger cohorts are required to validate these findings.
- Published
- 2024
- Full Text
- View/download PDF